Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001919105 | SCV002179131 | pathogenic | Ataxia-telangiectasia syndrome | 2022-06-20 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Tyr316*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). |
Baylor Genetics | RCV003471044 | SCV004212225 | likely pathogenic | Familial cancer of breast | 2022-09-01 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV003471044 | SCV004930459 | pathogenic | Familial cancer of breast | 2024-01-11 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |